Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
Eton Pharmaceuticals, Inc. (ETON)
Last eton pharmaceuticals, inc. earnings: 3/5 04:02 pm
Check Earnings Report
Company Research
Source: GlobeNewswire
Management to Hold Investor Day Conference Call Today at 10:00am ET Reported record product revenue of $11.6 million in Q4 2024, an increase of 59% over Q4 2023, representing the 16th straight quarter of sequential product sales growthClosed the transformational acquisition of pediatric endocrinology biologic Increlex® and relaunched the product in JanuaryAcquired and relaunched ultra rare disease product Galzin®Licensed U.S. rights to late-stage pipeline candidate Amglidia®, further boosting the Company’s pediatric endocrinology pipelineAnnounced positive pivotal clinical study results for ET-600; preparing for an April 2025 NDA submissionManufactured ET-400 launch inventory in preparation for a potential approval on its PDUFA go
Read more
Impact Snapshot
Event Time:
ETON
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ETON alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ETON alerts
High impacting Eton Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
ETON
News
- ESTEVE signs a licensing agreement for a severe primary insulin-like growth factor 1 deficiency treatment [Yahoo! Finance]Yahoo! Finance
- Eton Pharmaceuticals Out-Licenses International Rights to Increlex®GlobeNewswire
- Eton Pharmaceuticals, Inc. (NASDAQ: ETON) had its price target raised by analysts at Craig Hallum from $23.00 to $26.00. They now have a "buy" rating on the stock.MarketBeat
- Eton Pharmaceuticals, Inc. (NASDAQ: ETON) had its "buy" rating re-affirmed by analysts at B. Riley. They now have a $24.00 price target on the stock, up previously from $21.00.MarketBeat
- Eton Pharmaceuticals, Inc. (NASDAQ: ETON) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.MarketBeat
ETON
Earnings
- 3/18/25 - Miss
ETON
Sec Filings
- 4/1/25 - Form 8-K
- 3/18/25 - Form 8-K
- 3/18/25 - Form 8-K
- ETON's page on the SEC website